OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Touijer on Surgical Options for Patients with RCC

November 9th 2016

Karim A. Touijer, MD, MPH, surgeon, Memorial Sloan Kettering Cancer Center, discusses the considering factors for surgical options for patients with renal cell carcinoma (RCC).

Dr. Brown on Recent Progress in the Treatment Landscape of CLL

November 8th 2016

Jennifer R. Brown, MD, PhD, Director, CLL Center, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the recent progress seen in the treatment landscape of chronic lymphocytic leukemia (CLL), and what still needs to be accomplished going forward.

Dr. Witzig on Emerging Agents in Diffuse Large B-Cell Lymphoma

November 8th 2016

Thomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the emerging agents being utilized in the treatment of patients with diffuse large B-cell lymphoma.

Dr. Llombart-Cussac on Eribulin in HER2-Negative Metastatic Breast Cancer

November 8th 2016

Antonio Llombart-Cussac, MD, PhD, chairman of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study, which assessed first-line eribulin (Halaven) for taxane-resistant patients with HER2-negative metastatic breast cancer.

Dr. Hsieh on Patient Characterization From RECORD-3 Study in Metastatic RCC

November 8th 2016

James J. Hsieh, MD, medical oncologist, physician-scientist, Memorial Sloan Kettering Cancer Center, discusses overall survival results in the RECORD-3 study based on 3 distinct clear cell metastatic renal cell carcinoma molecular subgroups.

Dr. Uzzo on Potential of Adjuvant Therapy in Patients With RCC

November 8th 2016

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of Surgery, Temple University Health System, Fox Chase Cancer Center, discusses recent outcomes of adjuvant therapy as seen in clinical trials for patients with renal cell carcinoma (RCC).

Dr. Rahul Tendulkar on Managing Side Effects of Radical Prostatectomy

November 7th 2016

Rahul Tendulkar, MD, associate staff, radiation oncology, Cleveland Clinic, discusses the side effects of a radical prostatectomy for men with prostate cancer.

Dr. Mikhail Fedyanin on Mutation Discordance and Liquid Biopsy in CRC

November 5th 2016

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC), as well as the benefits of liquid biopsy.

Dr. Yuh on Outcomes Between RT and Surgery in Prostate Cancer

November 4th 2016

Bertram Yuh, MD, an assistant clinical professor of Urologic Oncology and a urologic oncology surgeon at City of Hope, compares the outcomes with surgery and radiation treatment in patients with localized prostate cancer. Yuh shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Dr. Duvic on Importance of Classifying T-Cell Lymphomas

November 4th 2016

Madeleine Duvic, MD, professor of Medicine and Dermatology, Blanche Bender Professorship in Cancer Research, director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of classifying T-cell lymphomas and new targets in development. Duvic shared this insight during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.

Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma

November 4th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the role for immunotherapy and targeted agents in patients with BRAF-positive melanoma.

Dr. Alice T. Shaw on Ceritinib for Frontline ALK+ NSCLC With Brain Metastases

November 4th 2016

Alice T. Shaw, MD, PhD, thoracic oncologist at the Massachusetts General Hospital Cancer Center, discusses ceritinib in newly diagnosed patients with ALK-positive non-small cell lung cancer (NSCLC) and brain metastases.

Dr. Mohammed Haseebuddin on Expanding Role for Immunotherapy in RCC

November 3rd 2016

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discuses why continued research into immunotherapy in clear cell renal cell carcinoma (RCC) is important, particularly in the adjuvant and neoadjuvant settings.

Dr. David L. Rimm on the Continued Role for PD-L1 Testing in NSCLC

November 3rd 2016

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the continued role for PD-L1 testing to predict response with checkpoint inhibitors in non–small cell lung cancer (NSCLC).

Jena D. French on Anti-PD-1/Lenvatinib Combo in Differentiated Thyroid Cancer

November 3rd 2016

Jena D. French, PhD, instructor of medicine, division of endocrinology, metabolism and diabetes, Anschutz Medical Campus, University of Colorado, discusses the potential for immunotherapy combinations with lenvatinib in differentiated thyroid cancer.

Dr. Pal on Sequencing Challenges for the Treatment of Patients With RCC

November 3rd 2016

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the challenges with sequencing the therapies available for patients with renal cell carcinoma (RCC). Pal shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Dr. Garcia-Manero on Curing Patients With MDS and AML

November 2nd 2016

Guillermo Garcia-Manero, MD, professor of Medicine, chief, Section of Myelodysplastic Syndromes, in the Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of curing patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Garcia-Manero explained this reasoning in an interview during the 2016 OncLive State of the Science Summit on Treatment of Hematologic Malignancies.

Dr. DeCamp on Platforms of Surgical Management in Lung Cancer

November 2nd 2016

Malcolm McAvoy DeCamp, Jr, MD, chief of Thoracic Surgery in the Department of Surgery, Northwestern University Feinberg School of Medicine, discusses different platforms of surgical management in the treatment of patients with lung cancer.

Dr. Schoenfeld on Preventing Immune Suppression With Radiation and Immunotherapy Combos

November 2nd 2016

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses challenges with immune suppression with radiation and immunotherapy combinations.

Dr. Elizabeth H. Baldini on Systemic Therapy for Sarcoma

November 2nd 2016

Elizabeth H. Baldini, MD, MPH, director, radiation oncology, center for sarcoma and bone oncology, associate professor of radiation oncology, Harvard Medical School, discusses sarcoma